financetom
Business
financetom
/
Business
/
Michigan seeks comment on permit to increase Marathon refinery throughput
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Michigan seeks comment on permit to increase Marathon refinery throughput
Apr 18, 2024 9:41 AM

April 18 (Reuters) - A Michigan regulator said this week

it is seeking public comment on a proposed permit that would

allow Marathon Petroleum ( MPC ) to boost crude throughput at

its Detroit refinery.

Marathon filed an application with the state in March to run

its 140,000 barrel per day refinery continuously at full

capacity by removing monthly and annual throughput limits. The

plan is opposed by local environmental groups because increasing

throughput increases refinery pollution.

The refinery's current permit caps the facility's capacity

at 140,000 barrels per day (bpd) on an annual average.

Marathon currently relies on periods of shutdown or reduced

production to meet the annual average limit, a spokesperson for

the Michigan Department of Environment, Great Lakes, and Energy

said.

Marathon declined to comment on whether it plans to

boost throughput beyond 140,000 bpd.

The Detroit refinery emits less pollutants than its current

permit allows, according to Marathon and regulators.

The facility is located in Wayne County, Michigan, an area

with significant industry presence that is out of compliance

with national standards for sulfur dioxide emissions.

To offset pollution increases, Marathon has proposed several

projects including upgrading process heaters to phase out the

crude flare.

Marathon has violated air quality rules and regulations

in the past, but that cannot prevent Marathon from seeking this

permit, regulators said.

The company lost an appeal in 2022 to be exempt from a rule

requiring it to enclose petroleum coke at the Detroit refinery

in order to prevent dust from being released.

A public hearing on the proposed permit is scheduled for May

22.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
PennyMac Financial Services to Offer $650 Million Senior Notes Due 2033
PennyMac Financial Services to Offer $650 Million Senior Notes Due 2033
Feb 4, 2025
08:18 AM EST, 02/04/2025 (MT Newswires) -- PennyMac Financial Services ( PFSI ) said Tuesday it plans to offer $650 million in senior notes due 2033. Proceeds from the offering will be used to repay certain debt, including borrowings under secured MSR facilities, repurchase a portion of its 5.375% senior notes due October 2025, and for general corporate purposes, the...
iA Financial Acquires Global Warranty to Add Used-Car Warranty Business
iA Financial Acquires Global Warranty to Add Used-Car Warranty Business
Feb 4, 2025
08:21 AM EST, 02/04/2025 (MT Newswires) -- iA Financial ( IAFNF ) on Tuesday said it agreed to acquire Global Warranty for an undisclosed price to add its used-car warranty business. The insurer and finance company said Global Warranty has a network of 1,500 auto dealerships and 400 repair shops where it provides insured warranty packages on vehicles. iA said...
Fox Fiscal Q2 Adjusted Earnings, Revenue Rise
Fox Fiscal Q2 Adjusted Earnings, Revenue Rise
Feb 4, 2025
08:17 AM EST, 02/04/2025 (MT Newswires) -- Fox (FOX) reported fiscal Q2 adjusted earnings Tuesday of $0.96 per diluted share, compared with $0.34 a year earlier. Analysts surveyed by FactSet expected $0.69. Revenue for the quarter ended Dec. 31 was $5.08 billion, compared with $4.23 billion a year earlier. Analysts surveyed by FactSet expected $4.87 billion. Fox shares were up...
Regeneron beats quarterly estimates on eczema drug demand; launches dividend program
Regeneron beats quarterly estimates on eczema drug demand; launches dividend program
Feb 4, 2025
(Reuters) - Regeneron Pharmaceuticals ( REGN ) beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback program, sending its shares up 2.2% premarket. U.S. sales of Eylea, which has been its long-standing cash cow, rose by 2% to $1.5 billion, including $305 million from the higher...
Copyright 2023-2026 - www.financetom.com All Rights Reserved